百克生物公告，预计2025年年度实现归属于母公司所有者的净利润亏损2.2亿元到2.8亿元，与上年同期 相比，减少4.52亿元到5.12亿元，同比减少194.79%到220.64%。预计2025年年度实现归属于母公司所有 者扣除非经常性损益后的净利润亏损2.4亿元到3亿元，与上年同期相比，减少4.7亿元到5.3亿元，同比 减少204.43%到230.54%。报告期内，受行业竞争加剧、民众接种意愿不足、新生儿出生率下降等多重 因素影响，公司经营环境面临阶段性挑战，2025年度净利润亏损。 ...

Core Viewpoint - The company has approved a profit distribution plan for the first half of 2025, which aligns with its actual situation and complies with relevant laws and regulations, aiming to ensure sustainable and stable development [1][2][3] Summary by Sections 1. Review Process - The board of directors believes the profit distribution plan is legitimate, compliant, and reasonable, matching the company's development strategy [1][2] - The supervisory board agrees with the proposal, stating it aligns with the company's actual situation and regulations regarding cash dividends [1][2] 2. Profit Distribution Plan Details - The net profit attributable to shareholders for the first half of 2025 is 43,160,638.40 yuan, while the parent company's net profit is 2,727,762,437.59 yuan [2] - The total undistributed profits as of June 30, 2025, are 3,056,170,567.46 yuan for the consolidated statements and 2,999,321,198.71 yuan for the parent company [2] - The proposed cash dividend is 0.30 yuan per 10 shares (including tax), with no stock dividends or capital reserve transfers [2][3] 3. Reasonableness of the Profit Distribution Plan - The plan considers industry characteristics, development stage, operating model, profitability, debt repayment ability, and future funding needs [3] - It aims to balance reasonable returns for shareholders while ensuring the company's operational and developmental needs are met [3]